Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4851 USD | -5.99% | -11.02% | -10.71% |
Mar. 22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
Mar. 14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Financials (USD)
Sales 2024 * | 36.94M | Sales 2025 * | 64.14M | Capitalization | 98.8M |
---|---|---|---|---|---|
Net income 2024 * | -109M | Net income 2025 * | -82M | EV / Sales 2024 * | 3.78 x |
Net Debt 2024 * | 40.79M | Net Debt 2025 * | 129M | EV / Sales 2025 * | 3.55 x |
P/E ratio 2024 * |
-0.97
x | P/E ratio 2025 * |
-1.58
x | Employees | 405 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.55% |
Latest transcript on Sangamo Therapeutics, Inc.
1 day | -5.99% | ||
1 week | -11.02% | ||
Current month | -27.62% | ||
1 month | -43.00% | ||
3 months | +16.69% | ||
6 months | -9.50% | ||
Current year | -10.71% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 46 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 58 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.66% | 2 M€ | -25.75% | ||
0.49% | 16 M€ | -9.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.4851 | -5.99% | 1,744,218 |
24-04-17 | 0.516 | -4.80% | 1,169,195 |
24-04-16 | 0.542 | -2.36% | 992,597 |
24-04-15 | 0.5551 | +2.15% | 1,708,055 |
24-04-12 | 0.5434 | -0.33% | 1,350,251 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.71% | 98.8M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.98% | 21.66B | |
-18.35% | 20.77B | |
-8.56% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- SGMO Stock